82 |
Chiong E., Murphy D.G., Buchan N.C., Chua M.L.K., Hakim L., Hamid A.R., Hong S.K., Horvath L.G., Kanesvaran R., Khochikar M., Letran J., Lojanapiwat B., Malek R., Ng A.C.F., Vinh N.T., Pang S.-T., Poon D.M.C., Ong T.A., Saad M., Schubach K., Shiroki R., Türkeri L., Williams S., Wong A., Ye D., Davis I.D., ANZUP Cancer Trials Group |
Managing advanced prostate cancer in the Asia Pacific region: “Real-world” application of Advanced Prostate Cancer Consensus Conference 2019 statements |
2022 |
Asia-Pacific Journal of Clinical Oncology |
2 |
Department of Urology, National University Hospital, National University Health System, Singapore; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia; Department of Urology, Christchurch Hospital, Christchurch, New Zealand; Divisions of Radiation Oncology and Medical Sciences, National Cancer Centre Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore; Department of Urology, Faculty of Medicine, Airlangga University/Airlangga University Hospital, Surabaya, Indonesia; Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Urology, Seoul National University Bundang Hospital, Seongnam-si, South Korea; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Department of Uro-oncology, Siddhi Vinayak Ganapati Cancer Hospital, Miraj, India; Section of Urology, Chinese General Hospital and Medical Center, Manila, Philippines; Division of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Department of Urology, Selayang Hospital, Kuala Lumpur, Malaysia; SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong; Department of Urology, Binh dan Hospital, Ho Chi Minh City, Viet Nam; Department of Urology, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan; Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong; Division of Urology, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Department of Clinical Oncology, University of Malaya Medical Centre, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Men's Health Melbourne, Melbourne, VIC, Australia; Australian and New Zealand Urology Nurses Society (ANZUNS), Australia; ANZUP Cancer Trials Group, Sydney, NSW, Australia; Department of Urology, Fujita Health University, Nagoya, Japan; Department of Urology, Acıbadem M.A. Aydınlar University, Istanbul, Turkey; Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Department of Haematology Oncology, National University Hospital, Singapore; Department of Urology, Shanghai Cancer Center, Shanghai, China; Monash University, Melbourne, VIC, Australia; Eastern Health, Melbourne, VIC, Australia |
|
John Wiley and Sons Inc |
Q3 |
|
|